Table 5.

Efficacy of Multiple Agents of Different Classes in the OH-BBN Rat Urinary Bladder Cancer Model or the UV-Induced Model of Squamous Cell Carcinomas in SKH Mice

ModelClass of AgentsSpecific AgentDoseCancer Multiplicity Decrease (%)References
OH-BBN RatNSAIDNaproxen400 ppm>806, 48
OH-BBN RatNSAIDNo-Naproxen560 ppm>8048
OH-BBN RatNSAIDSulindac400 ppm>8048
OH-BBN RatCoxibCelecoxib1000 ppm>8044,45,46
OH-BBN RatEGFR InhibitorGefitinib10 mg/Kg BW>806
OH-BBN RatEGFR InhibitorLapatinib75 mg/Kg BW>80Unpublished
OH-BBN RatEGFR InhibitorErlotinib6 mg/Kg BW>80Unpublished
Decrease in SCCs
UV MiceNSAIDIndomethacin400 ppm>8044
UV MiceNSAIDNo -Naproxen560 ppm>8043
UV MiceNSAIDSulindac150 ppm>8043
UV-MiceNSAIDNaproxen400 PPM>80%43
UV MiceNSAIDAspirin560 ppm>8043
UV MiceCoxibCelecoxib1000 ppm>8043,44
  • aOH-BBN Rat - Agents in bold also effective when administered 14 weeks after last OH-BBN when roughly 50% of rats have microcarcinomas.

  • bUV Mice - Agent in bold effective in UV exposed mice when they already have substantial papilloma and SCC burden. Thus, celecoxib, for example, could cause regression of lesions.